

Genetically Engineered Mengo Virus Vaccination of Multiple Captive Wildlife Species

Kay A. Backues,¹ Marchel Hill,² Ann C. Palmenberg,² Christine Miller,³ Kenneth F. Soike,⁴ and Roberto Aguilar,^{5,1} Tulsa Zoo and Living Museum, 5701 East 36th Street North, Tulsa, Oklahoma 74155, USA; ² Dept. of Biochemistry, University of Wisconsin, 433 Babcock Drive, Madison, Wisconsin, 53706, USA; ³ Miami Metro Zoo, 12400 SW 152nd Street, Miami, Florida 33186, USA; ⁴ Delta Regional Primate Center, Three Rivers Road, Covington, Louisiana 70119, USA; ⁵ Audubon Park Zoological Gardens, 6500 Magazine Street, New Orleans, Louisiana 70118, USA; ⁶ Corresponding author (e-mail: kbackues@ci.tulsa.ok.us).

ABSTRACT: Encephalomyocarditis virus (EMCV), has caused the deaths of many species of animals in zoological parks and research institutions. The Audubon Park Zoo, (New Orleans, Louisiana, USA) attempted vaccination of several species with a killed EMCV vaccine with mixed results. This paper reports an attempt at vaccination against EMCV using a genetically engineered, live attenuated Mengo virus (vMCO) at the Audubon Park Zoo and Miami Metro Zoo, (Miami, Florida, USA) from December 1996 to June 1997. Several species of animals were vaccinated with vMCO, which is serologically indistinguishable from the field strain of EMCV. Serum samples were taken at the time of vaccination and again 21 days later, then submitted for serum neutralization titers against EMCV. The vaccinee species included red capped manglebeey (*Cercopithecus torquatus*), colobus (*Colobus guereza*), angolan colobus (*Colobus angolensis*), ruffed lemur (*Lemur variegatus ruber* and *Lemur variegatus variegatus*), black lemur (*Lemur macaco*), ring-tailed lemur (*Lemur catta*), siamang (*Hylobates syndactylus*), diana guenon (*Cercopithecus diana*), spider monkey (*Ateles geoffroyi*), common marmoset (*Callithrix jacchus*), talapoin monkey (*Cercopithecus talapoin*), Brazilian tapir (*Tapirus terrestris*), Baird's tapir (*Tapirus bairdii*), Malayan tapir (*Tapirus indicus*), dromedary camel (*Camelus dromedarius*), bactrian camel (*Camelus bactrianus*), gerenuk (*Litocranius walleri*), guanaco (*Lama glama guanicoe*), black duiker (*Cephalophus niger*), Vietnamese potbellied pig (*Sus scrofa*), babirusa (*Babirusa babyrussa*), collard peccary (*Tayass tajacu*), and African crested porcupine (*Hystrix africaeaustralis*). The vaccine response was variable, with high virus neutralizing antibody titer responses in some primate species and mixed to poor responses for other species. No ill effects were seen with vaccination.

Key words: *Cardiovirus*, Encephalomyocarditis virus, Mengo virus, seroconversion, serum virus neutralizing antibody titer, vaccination.

Encephalomyocarditis virus (EMCV) is a member of the family Picornaviridae. The genus *Cardiovirus* contains EMCV

and Mengo virus, which are serologically indistinguishable (Zimmerman, 1994), as well as other serologically dissimilar viruses. Transmission and maintenance of cardioviruses is thought to be through murine rodents, although arthropod vectors are occasionally implicated (Wells et al., 1989; Zimmerman, 1994). It is felt that both the original and recent outbreaks of EMCV at the Audubon Zoo (New Orleans, Louisiana, USA) were associated with high numbers of rodents.

Disease caused by EMCV is peracute, seen as sudden death or anorexia and depression observed 12 to 24 hr before death (Gutter, 1993). Gross lesions are typically limited to the cardiopulmonary system. Findings include hydropericardium, pale streaks throughout the myocardium, and pulmonary edema (Gutter, 1993). Histologically, lesions may show massive cardiac myocyte necrosis with edema and lymphocytic, plasmacytic, and histocytic infiltrates. Pulmonary lesions of edema and congestion are secondary to acute cardiac failure (Gutter, 1993). Most viruses of the genus *Cardiovirus* contain a unique homopolymeric polyribocytidylate sequence within their 5' non-coding RNA segments, that may contain from 60 to 420 pyrimidine nucleotides in a row (Martin et al., 1996). These poly(C) tracts and their particular lengths have been directly correlated with the virus's pathogenicity (Osorio et al., 1996b). Genetically engineered live Mengo viruses with shortened poly(C) tracts have been shown to be dramatically attenuated in animals, and moreover to steadfastly maintain their artificially truncated sequences during serial tissue culture pas-

sage (Palmenberg and Osorio, 1994). Laboratory mice receiving the short-tract strains developed life-long protective immunity against normally lethal challenge with wildtype Mengo or EMCV (Osorio et al., 1996b). Vaccination with a variety short poly(C) Mengo viruses has been shown to protect macaques, baboons and domestic swine as well as mice when challenged with wildtype EMCV (Osorio et al., 1996a). The objective of the current project was to determine whether inoculated target species at the Audubon Park Zoo and Miami Metro Zoological Park. (Miami, Florida, USA) would seroconvert when inoculated with a genetically engineered shortened poly(C) Mengo virus.

Mengo virus (vMC0) was grown from a plaque that resulted after transfection of HeLa cells with T7 RNA transcripts of cDNA origin (Martin et al., 1996). For intramuscular inoculation studies, suspensions of HeLa cells infected with vMC0 were clarified by centrifugation (10,000 g for 30 min, 4°C), followed by ultra centrifugation through a 30% sucrose cushion. The resuspended pellet was stored at 4°C (Osorio et al., 1996a). From December 1996 through June of 1997 the following species were vaccinated at the Audubon Park Zoo and Miami Metro Zoo: red capped manglebe (*Cercocebus torquatus*), colobus (*Colobus guereza*), angolan colobus (*Colobus angolensis*), ruffed lemur (*Lemur variegatus ruber* and *Lemur variegatus variegatus*), black lemur (*Lemur macaco*), ring-tailed lemur (*Lemur catta*), siamang (*Hylobates syndactylus*), diana guenon (*Cercopithecus diana*), spider monkey (*Ateles geoffroyi*), common marmoset (*Callithrix jacchus*), talapoin monkey (*Cercopithecus talapoin*), Brazilian tapir (*Tapirus terrestris*), Baird's tapir (*Tapirus bairdii*), Malayan tapir (*Tapirus indicus*), dromedary camel (*Camelus dromedarius*), bactrian camel (*Camelus bactrianus*), genenuk (*Litocranius walleri*), guanaco (*Lama glama guanicoe*), black duiker (*Cephalophus niger*), Vietnamese potbellied pig (*Sus scrofa*), babirusa (*Babyrousa ba-*

byrussa), collard peccary (*Tayass tajacu*), and African crested porcupine (*Hystrix africae australis*). The animals were injected intramuscularly during annual physical examinations with 5.0×10^6 PFU (plaque-forming units) of the prepared supernatant. The concentration was achieved by serial dilution of the virus with phosphate buffered saline to a 0.5 ml dose volume. To minimize the number of times an animal was handled, no prescreening titers were performed. Blood samples were collected immediately prior to vaccination, and again in 21 days. The blood was allowed to clot for 20 min at room temperature and then centrifuged at 10,000 g for 5 min to separate the serum. Serum samples were stored at -20°C until analysis. Samples were tested by two independent laboratories for serum microneutralization titers to EMCV using 2 fold serial dilutions of serum samples (Hubbard et al., 1992; Osorio et al., 1996a). Seroconversion was considered to be a four fold increase in serum titer.

Table 1 summarizes the serum virus neutralizing antibody titer results for all tested animals. In many primates without pre-existing titers ($1:<8$) to EMCV there was greater than a four fold serum titer increase at day 21. Several animals had preexisting titers (>8) to EMCV which indicated exposure to a wildtype *Cardiovirus*. For some of these animals, their pre-existing high titer may have interfered with vMC0 vaccine replication or acted as a booster by increasing their low pre-vaccination titers. Many animals, primarily primates, had at least a four fold increase in titer indicating seroconversion to vMC0 vaccination. However, in other species, such as the camels, common marmosets and lemurs, only minimum increases in serum virus neutralizing antibody titers were seen or there were none at all.

EMCV is a peracute disease that can cause devastating losses to a zoological collection. One of the most important components of EMCV mortality prevention is an effective and consistent rodent control

TABLE 1. EMCV titers by serum microneutralization to genetically engineered Mengo virus (vMCO) for multiple captive species.

Species	Animal number											
	1	2	3	4	5	6	7	8	9	10	11	
<i>Ateles geoffroyi</i>	16/16 ^a	<8/64										
<i>Babirusa babyrussa</i>	<8/8	<8/128	<8/512									
<i>Callithrix jacchus</i>	16/16	64/64	16/16									
<i>Camelus bactrianus</i>	<16/32	16/16	<16/8									
<i>Camelus dromedary</i>	<8/128	<8/>32	8/32	<16/64	8/8	8/8	8/8					
<i>Cephalophus niger</i>	<8/64											
<i>Cercocebus torquatus</i>	<8/8	<8/64	<8/128	<8/>128	<8/>8	<8/>32						
<i>Cercopithecus diana</i>	<8/128	<8/>64										
<i>Cercopithecus talapoin</i>	<8/256	<8/256	<8/128	<8/256	<8/256	<8/256						
<i>Colobus angolensis</i>	<8/8	<8/8	<8/128	8/128	8/256	<8/256	<8/64	<8/32	<8/128	<8/64	<8/64	
<i>Colobus guereza</i>	<8/256	<8/8	<8/64	<8/128								
<i>Hylobates syndactylus</i>	128/256	128/512										
<i>Hystrix africaeaustralis</i>	<8/128	<8/64										
<i>Lama glama guanicoe</i>	>16/128											
<i>Lemur catta</i>	<8/8	<8/8	<8/8	<8/16	<8/16	<8/32						
<i>Lemur macaco</i>	<8/8	<8/8	<8/8									
<i>Lemur variegatus ruber</i>	<8/8	<8/8	<8/8									
<i>Lemur variegatus variegatus</i>	32/512	<8/>32										
<i>Litocranius walleri</i>	<16/128	<8/256	8/128	32/512	<16/64	<8/64	<8/64	<16/64				
<i>Sus scrofa</i>	<8/32	<8/16	<16/32									
<i>Tapirus bairdii</i>	512/512	32/32	<8/256	<8/32								
<i>Tapirus indicus</i>	512/256	<8/8										
<i>Tapirus terrestris</i>	512/512	256/512	256/512									
<i>Tayassu tajacu</i>	32/256											

^a Serum neutralization (SN) antibody titer at day 0/SN antibody titer at day 21 post vaccination.

program. However, based on responses seen in this study where seroconversion was considered to be a four fold increase in serum virus neutralizing antibody titers, vaccination with vMC0 may also be a weapon to prevent mortality due to EMCV. This live attenuated virus did not produce visible disease; change in attitude, appetite or activity levels in any tested animals. Vaccination did produce a four fold serum virus neutralizing antibody titer increases in many inoculated animals. In individuals that did not develop a measurable titer it is not known whether the vaccine was ineffective or if more time was needed to see a measurable titer increase. Those animals may have had an amebiotic response to a second "booster" vaccination. It is not known whether the titers achieved would be protective against wild-type EMCV challenge in the species vaccinated. Based on laboratory animal challenges, serum virus neutralizing antibody titers of >1:16 are known to be protective, and possibly confer lifelong immunity to baboons, domestic pigs and mice (Osorio et al., 1996a). A virulent challenge was deemed inappropriate in a zoological setting and was not performed. However, rising antibody responses without any observed vaccination related complications suggest possible successful vaccination in some cases. It is hoped that a commercially available modified live virus vaccine, based on vMC0 will become available to aid in the protection of captive wildlife from EMCV morbidity and mortality.

The authors thank J. Joyner, S. MacConnell, and the Audubon Park and Miami Metro Zoo's Mammal Departments for their assistance. M. Hill is supported by NIH grant AI-30566 to A. C. Palmenberg.

LITERATURE CITED

- GUTTER, A. E. 1993. Encephalomyocarditis in zoo animals. *In Zoo and Wild Animal Medicine*, M. E. Fowler (ed.). W. B. Saunders Co., Philadelphia, Pennsylvania, pp. 50–51.
- HUBBARD, G. B., K. F. SOIKE, T. M. BUTLER, K. D. CAREY, H. DAVIS, W. I. BUTCHER, AND C. J. GAUNTT. 1992. An encephalomyocarditis virus epizootic in an baboon colony. *Laboratory Animal Science* 42: 233–239.
- MARTIN, L. R., G. M. DUKE, J. E. OSORIO, D. J. HALL, AND A. C. PALMENBERG. 1996. Mutational analysis of the mengovirus poly(C) tract and surrounding heteropolymeric sequences. *Journal of virology* 70: 2027–2030.
- OSORIO, J. E., G. B. HUBBARD, K. F. SOIKE, M. GIRARD, S. VAN DER WERF, J. C. MOULIN, AND A. C. PALMENBERG. 1996a. Protection of non-murine mammals against encephalomyocarditis virus using a genetically engineered Mengo virus. *Vaccine* 14: 155–161.
- , L. R. MARTIN, AND A. C. PALMENBERG. 1996b. The immunogenic and pathogenic potential of short Poly(C) tract Mengo viruses. *Virology* 223: 344–350.
- PALMENBERG, A. C., AND J. E. OSORIO. 1994. Cardiovascular poly(C) tracts and viral pathogenesis. *Archives Virology(Suppl)* 9: 67–77.
- WELLS, S. K., A. E. GUTTER, K. F. SOIKE, AND G. B. BASKIN. 1989. Encephalomyocarditis virus: epizootic in a zoological collection. *Journal of Zoo and Wildlife Medicine* 20: 291–296.
- ZIMMERMAN, J. J. 1994. Encephalomyocarditis. *In Handbook of Zoonoses, Section B. Viral*, G. W. Beran (ed.). CRC Press, Boca Raton, Florida, pp. 423–436.

Received for publication 13 May 1998.